- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02622711
Promoting Weight Loss Through Diet and Exercise in Overweight Women With Breast Cancer (InForma)
January 29, 2020 updated by: European Institute of Oncology
Promoting Weight Loss Through Diet and Exercise in Overweight Women With Breast Cancer: A Four-arm Randomized Trial
The investigators aim to evaluate the effect of a 6-month intervention (counseling) focused on weight loss in a group of overweight or obese women previously treated for early breast cancer.
Intervention is designed to improve adherence to a healthy diet or/and to increase physical activity and decrease sedentary time, taking advantage of a pedometer-like device.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The InForma project is designed as a mono-institutional randomized controlled 4-arm parallel-group trial.
Potential study participants will be recruited among all overweight or obese breast cancer patients previously treated at the European Institute of Oncology (IEO).
Potential study participants will be recruited after breast cancer treatments (surgery, chemotherapy and and/or radiation) will be completed.
Study participants will be randomized to one of the 4 arms: DI - Dietary Intervention; PAI - Physical Activity Intervention; PADI - Physical Activity and Dietary Intervention; LII - Less Intensive Intervention.
Enrolled patients will receive a 6-month intervention and will be followed until the end of the study period with two additional follow-up visits at 12- and 24-month.
The main aim of the study is to evaluate the impact of the intervention programme on body weight change in overweight or obese breast cancer patients.
Study Type
Interventional
Enrollment (Actual)
262
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Milan, Italy, 20141
- IEO Istituto Europeo di Oncologia
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- diagnosed with a first invasive non-metastatic breast carcinoma histologically confirmed,
- BMI > 25,
- within 6-month/one year of completion of main cancer treatment,
- being able to participate in the intervention,
- agree to wear the wrist-based activity monitor during the study period,
- agree to be randomized to either group,
- written informed consent.
Exclusion Criteria:
- severe medical condition or advanced age impeding the patient to adhere at the planned study follow-up period,
- contraindications to exercise due to history of heart condition, stroke, chest pain during activity or rest, severe hypertension
- orthopaedic disability that would prevent optimal participation in the physical activities prescribed,
- patient is unable to find transportation to the study location over the study period, - or
- plans to move away from Lombardy or to be out of town for more than 3 weeks during the study period.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: DI Dietary Intervention
Individualized dietary counselling to reduce body weight
|
Participants will be offered an individualized dietary counselling according to their lifestyle habits to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
Other Names:
|
|
EXPERIMENTAL: PAI Physical Activity Intervention
Individualized physical activity counseling to reduce body weight
|
Participants will be offered an individualized physical activity counseling according to their lifestyle habits to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
Other Names:
|
|
EXPERIMENTAL: PADI Physical Activity+Diet Intervention
Individualized dietary and physical activity counseling to reduce body weight
|
Participants will be offered an individualized dietary and physical activity counseling to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
Other Names:
|
|
EXPERIMENTAL: LII Less Intensive Intervention
Materials and guidelines available to general public
|
Participants will be considered as control group.
They will receive a general healthy counselling providing materials and guidelines available for the general public.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body weight reduction
Time Frame: baseline - 6 month
|
weight loss ≥5% of the baseline body weight via calibrated scales, stadiometer
|
baseline - 6 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Long-term body weight control
Time Frame: baseline - 12 month - 24 month
|
long-term weight control or maintenance via calibrated scales, stadiometer
|
baseline - 12 month - 24 month
|
|
Pedometer Step Count
Time Frame: baseline - 6 month - 12 month - 24 month
|
change in total step count via pedometer device with electronic data transmission
|
baseline - 6 month - 12 month - 24 month
|
|
Physical activity level
Time Frame: baseline - 6 month - 12 month - 24 month
|
change in physical activity and inactivity levels via IPAQ-International physical activity questionnaire
|
baseline - 6 month - 12 month - 24 month
|
|
Dietary intake
Time Frame: baseline - 6 month - 24 month
|
change in dietary intake via Food Frequency Questionnaire
|
baseline - 6 month - 24 month
|
|
Quality of life
Time Frame: baseline - 6 month - 12 month - 24 month
|
change in quality of life via Functional Assessment of Cancer Therapy-Breast (FACT-B)
|
baseline - 6 month - 12 month - 24 month
|
|
Mood
Time Frame: baseline - 6 month - 12 month - 24 month
|
change in mood via State-Trait Anxiety Inventory (STAI) questionnaires
|
baseline - 6 month - 12 month - 24 month
|
|
Lipid Marker Change
Time Frame: baseline - 6 month - 24 month
|
change in LDL, HDL, triglycerides and cholesterol assessed by blood samples
|
baseline - 6 month - 24 month
|
|
Oestradiol level
Time Frame: baseline - 6 month - 24 month
|
change in oestradiol assessed by blood samples
|
baseline - 6 month - 24 month
|
|
Insulin level
Time Frame: baseline - 6 month - 24 month
|
change in insulin assessed by blood samples
|
baseline - 6 month - 24 month
|
|
Glucose level
Time Frame: baseline - 6 month - 24 month
|
change in glucose assessed by blood samples
|
baseline - 6 month - 24 month
|
|
C-reactive protein level
Time Frame: baseline - 6 month - 24 month
|
change in C-reactive protein assessed by blood samples
|
baseline - 6 month - 24 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Patrick Maisonneuve, European Institue of Oncology
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
November 1, 2015
Primary Completion (ACTUAL)
June 30, 2019
Study Completion (ACTUAL)
June 30, 2019
Study Registration Dates
First Submitted
November 6, 2015
First Submitted That Met QC Criteria
December 2, 2015
First Posted (ESTIMATE)
December 4, 2015
Study Record Updates
Last Update Posted (ACTUAL)
January 30, 2020
Last Update Submitted That Met QC Criteria
January 29, 2020
Last Verified
January 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IEO 0244
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
Clinical Trials on DI
-
BHB Therapeutics, Ireland LTDMérieux NutriSciences BiofortisCompleted
-
BHB Therapeutics, Ireland LTDMérieux NutriSciences BiofortisCompleted
-
University of ChicagoCompletedDepression | Depressive Disorder, MajorUnited States
-
Memorial University of NewfoundlandNL SUPPORT Strategy for Patient-Oriented ResearchCompleted
-
Assistance Publique - Hôpitaux de ParisTerminatedBrugada SyndromeFrance
-
Alopexx Oncology, LLCTerminatedB-cell Non-Hodgkin LymphomaUnited States
-
Alopexx Oncology, LLCTerminatedB-cell Non-Hodgkin LymphomaUnited States
-
Cancer Research UKCompletedChronic Lymphocytic Leukaemia | Indolent B-cell Lymphoma | Waldenström MacroglobulinaemiaUnited Kingdom
-
Radboud University Medical CenterCliniques universitaires Saint-Luc- Université Catholique de Louvain; University... and other collaboratorsRecruiting